Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.

Rhea-AI Summary

Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.

Analysis integrated longitudinal clinical and proteomic data from >650 participants and ~4,500 proteomic probes (median follow-up ≥2.5 years), linking subtypes to rapid progression, cognitive decline, and functional impairment. Lunai is initiating experimental validation, preclinical model development, and biomarker qualification while evaluating co-development opportunities in a market projected to exceed $13 billion by the 2030s.

Positive

• Three Parkinson's subtypes identified from subject-level analyses
• Data set: >650 participants and 4,500 proteomic probes
• Findings support biomarker-enriched patient selection and faster proof-of-concept
• Prioritized drug targets moved to experimental validation and preclinical development

Negative

• Target validation is preclinical and not yet clinically qualified
• Biomarker qualification and clinical utility remain unproven pending further studies

Argus Dec 9 session

-8.70% close to close Open Argus

Details

News Market Reaction – LNAI

On Dec 9, the day this news came out, LNAI closed 8.70% below the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Key Figures

Parkinson’s subtypes: 3 subtypes Participants: more than 650 participants Proteomic probes: 4,500 proteomic probes +5 more

Parkinson’s subtypes

3 subtypes

Clinically relevant Parkinson’s disease subtypes identified

Participants

more than 650 participants

Longitudinal clinical and proteomic data set

Proteomic probes

4,500 proteomic probes

Scale of proteomic measurements analyzed

Follow-up duration

median ≥2.5 years

Longitudinal tracking period for participants

Extended follow-up

many ≥5 years

Longer-term follow-up for subset of participants

Current PD market

$6–8 billion

Estimated current Parkinson’s disease market size

Projected PD market

$13 billion

Projected Parkinson’s market by the 2030s

Parkinson’s opportunity cited

$13 billion

Market size referenced for strategic partnerships

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Licensing LOI, oncology

   24h Move

   -15.0%

   Secured first LOI to license DC combination therapy after strong preclinical data.

2. Nov 05

   Preclinical cancer data

   24h Move

   +40.3%

   Reported complete regression of pancreatic tumors in humanized models with optimized DC therapy.

3. Oct 30

   AI neurotoxicity platform

   24h Move

   -2.0%

   Announced AI model with 0.94 AUROC for AChE inhibitor detection and zebrafish profiling plans.

4. Oct 16

   DMD biomarker study

   24h Move

   -1.6%

   Published large-scale serum proteomics study identifying prognostic biomarkers for DMD outcomes.

5. Oct 16

   Nasdaq compliance

   24h Move

   -1.6%

   Regained compliance with Nasdaq’s minimum bid requirement under Listing Rule 5550(a)(2).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

proteomic, proteomics, biomarker, companion diagnostics, +4 more

8 terms

proteomic medical

"integrated large-scale proteomic data from the Parkinson's Progression Markers"

Proteomic describes something related to the large-scale study of proteins—the working parts inside cells that carry out functions and signal changes. For investors, proteomic work can reveal new drug targets, diagnostic tests or biomarkers that change a company’s potential revenue and risk profile; think of it like analyzing all ingredients in a recipe to find which ones can be improved or swapped to make a better product.

proteomics medical

"using large-scale serum proteomics, and integrating phenomics, proteomics, and precision"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

biomarker medical

"supporting biomarker-enriched patient selection, accelerated proof-of-concept"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

companion diagnostics medical

"Co-develop biomarkers and companion diagnostics Translate pathway-level insights"

A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.

phenotyping medical

"with high-resolution clinical phenotyping to uncover subtypes associated"

Phenotyping is the process of measuring and categorizing observable characteristics of patients, diseases, or biological samples—such as symptoms, lab results, imaging features, or molecular markers—to create meaningful subgroups. For investors, phenotyping matters because it can improve drug trial design, target the right patients, reduce development risk, and reveal which tests or treatments will reach the market, much like profiling customers helps a company tailor and sell the right product.

longitudinal medical

"a landmark longitudinal study managed by The Michael J. Fox Foundation"

Longitudinal describes observations or data collected from the same subjects or entities repeatedly over time, tracking how things change rather than a single snapshot. For investors it matters because longitudinal information reveals trends, persistence, and potential cause-and-effect (for example in sales, safety outcomes, or earnings), helping distinguish short-term noise from meaningful long-term shifts—like watching a plant grow rather than looking at a single photo.

precision therapeutics medical

"an AI-powered biotechnology company developing precision therapeutics, today announced"

Precision therapeutics are medical treatments designed to match a therapy to an individual patient’s biology—such as a genetic profile, specific disease markers, or other measurable traits—so the most effective treatment reaches the right person. For investors, they matter because targeted therapies can improve success rates and command higher prices but often serve smaller patient groups and involve complex development and regulatory risks; think of them as a tailored suit versus off‑the‑rack clothing.

companion diagnostics medical

"Co-develop biomarkers and companion diagnostics Translate pathway-level insights"

A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SACRAMENTO, Calif., Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic development, and enable strategic co-development partnerships in a growing $13 billion market.

Using its proprietary Augusta Platform, Lunai Bioworks' wholly owned subsidiary BioSymetrics integrated large-scale proteomic data from the Parkinson's Progression Markers Initiative (PPMI), a landmark longitudinal study managed by The Michael J. Fox Foundation that tracks thousands of patients over time to identify biological markers of disease progression, with high-resolution clinical phenotyping to uncover subtypes associated with rapid progression, cognitive decline, and functional impairment. This analysis was recently highlighted in a recent article in Science Times.

The analysis integrated longitudinal clinical and proteomic data from more than 650 participants across 4,500 proteomic probes, tracked over multiple years (median ≥2.5 years, many ≥5 years). This scale enabled statistically robust identification of molecular signatures linked to rapid progression and worse outcomes, supporting biomarker-enriched patient selection, accelerated proof-of-concept, and higher probability of clinical and commercial success for subtype-specific therapeutics.

Subject-level analyses revealed three outcome-linked patient subtypes:

1. Fast motor progression with limited non-motor involvement
2. Rapid neurological and cognitive decline alongside motor worsening
3. A female-enriched subtype with broad functional impairment

These findings create an actionable foundation for inclusion, enrichment, and endpoint strategies designed to improve trial success rates, time to proof-of-concept, and asset valuation.

Proteomic and pathway-level evaluation identified progression-linked targets and biomarker candidates that may support baseline stratification, progression monitoring, and treatment-response assessment. Lunai is initiating experimental validation of prioritized targets and advancing toward preclinical model development and biomarker qualification.

"As Parkinson's therapy development continues to struggle with high failure rates and slow progression signals, subtype-specific strategies can materially improve outcomes," said David Weinstein, CEO of Lunai Bioworks. "By linking clinical trajectories to biological pathways, we can design smarter trials, identify partnerable targets, and accelerate development timelines in a highly competitive market."

In parallel, Lunai Bioworks is evaluating co-development and partnering opportunities with biopharmaceutical companies to:

• Apply subtype-specific inclusion criteria to existing Parkinson's assets
• Co-develop biomarkers and companion diagnostics
• Translate pathway-level insights into first-in-class therapeutics

"Integrating molecular biology with clinical phenotyping gives us a mechanism for identifying precision targets that could reshape how Parkinson's therapies are developed," said Dr. Gabe Musso, Chief Scientific Officer of BioSymetrics. "This will enable faster validation and more efficient partnering strategies."

Parkinson's disease represents a $6-8 billion market today, projected to exceed $13 billion by the 2030s, driven by rising prevalence and unmet need. Lunai Bioworks believes that by integrating phenomics, proteomics, and precision stratification, it can increase clinical success rates, shorten timelines, and support high-value partnerships.

About Lunai Bioworks
Lunai Bioworks Inc. (NASDAQ: LNAI) is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai Bioworks aims to redefine how artificial intelligence accelerates therapeutic innovation while safeguarding society from emerging threats. For more information, please visit: https://lunaibioworks.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding potential clinical impact, therapeutic benefit, development timelines, partnering strategy, and commercial value. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Lunai Bioworks undertakes no obligation to update forward-looking statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-identifies-three-parkinsons-subtypes-and-prioritized-drug-targets-to-accelerate-proof-of-concept-programs-and-strategic-partnerships-in-a-13b-market-302636013.html

SOURCE Lunai Bioworks Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Parkinson's subtypes did Lunai Bioworks (LNAI) identify on December 9, 2025?

Lunai reported three outcome-linked subtypes: fast motor progression, rapid neurological and cognitive decline, and a female-enriched subtype with broad functional impairment.

How large was the data set Lunai used to identify Parkinson's subtypes (LNAI)?

The analysis integrated longitudinal data from more than 650 participants across approximately 4,500 proteomic probes with median follow-up ≥2.5 years.

What next steps did Lunai Bioworks announce for its Parkinson's findings (LNAI)?

Lunai is initiating experimental validation of prioritized targets, advancing preclinical model development, and pursuing biomarker qualification and co-development partnerships.

How could Lunai's (LNAI) subtype discovery affect clinical trials?

The company says subtype-linked biomarkers enable inclusion and enrichment strategies designed to shorten time to proof-of-concept and improve trial success probability.

What market opportunity did Lunai (LNAI) cite for Parkinson's therapies?

Lunai referenced a Parkinson's market currently worth $6–8 billion and projected to exceed $13 billion by the 2030s.